{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:56:27Z","timestamp":1790747787665,"version":"4.1.0"},"reference-count":14,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2003,1,17]],"date-time":"2003-01-17T00:00:00Z","timestamp":1042761600000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2003,1]]},"abstract":"<jats:p><jats:bold>Summary:<\/jats:bold><jats:bold> \u2002Purpose: <\/jats:bold> Talampanel (LY300164), a potent and selective \u03b1\u2010amino\u20103\u2010hydroxy\u20105\u2010methyl\u20104\u2010isoxazolepropionate (AMPA)\u2010receptor antagonist, is a potential new antiepileptic drug (AED). This study examines the single\u2010 and multiple\u2010dose pharmacokinetics, safety, and tolerability of talampanel in patients with intractable epilepsy and assesses the potential for pharmacokinetic interaction.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Eleven of 14 patients entered into the study completed. Fourteen patients were evaluated for safety, 13 patients were used in the single\u2010dose, and 11 patients in the multiple\u2010dose pharmacokinetic analysis. Each patient initially received a single 35\u2010mg dose of talampanel followed by the measurement of pharmacokinetic profiles. A 21\u2010day t.i.d. dosing regimen was then determined for each patient based on his or her initial pharmacokinetic profile. Adverse events were recorded by patients or their carers.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> After oral ingestion, talampanel was rapidly absorbed, with maximal plasma concentrations achieved within 1\u20133 h. Talampanel concentrations in patients taking enzyme\u2010inducing AEDs were 50% lower than those seen in healthy volunteers. Mean talampanel t1\/2 values were 3.0 h compared with 4.2 h in healthy volunteers. After multiple\u2010dose and steady\u2010state, talampanel t1\/2 values were increased to 5.6 h Talampanel and valproic acid (VPA) appear to inhibit each other's metabolism mutually. Talampanel had no effect on plasma concentrations of other AEDs. Multiple\u2010dose talampanel administration was associated with nonlinear pharmacokinetics. No serious adverse events were reported; the most frequently reported being dizziness, ataxia, drowsiness, and headaches<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Talampanel dosing strategies may be reliant on concomitant AED medication, as enzyme\u2010inducing AEDs enhance, whereas VPA inhibits its metabolism. Talampanel was well tolerated, although adverse events occurred at lower doses compared with those in healthy subjects, probably because of the additive effect of concomitant AEDs.<\/jats:p>","DOI":"10.1046\/j.1528-1157.2003.128902.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T20:05:21Z","timestamp":1047413121000},"page":"46-53","source":"Crossref","is-referenced-by-count":69,"title":["Talampanel, a New Antiepileptic Drug: Single\u2010 and Multiple\u2010dose Pharmacokinetics and Initial 1\u2010Week Experience in Patients with Chronic Intractable\u2003Epilepsy"],"prefix":"10.1111","volume":"44","author":[{"given":"Yvonne\u2003M.","family":"Langan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Jewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Toublanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasemire\u2003W.\u2003A.\u2003S.","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip\u2003N.","family":"Patsalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,1,17]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"4","volume-title":"Emerging drugs: the prospect of improved medicines","author":"Patsalos PN","year":"1999"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.70.2.143"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(97)00188-3"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs0680113"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(98)00632-3"},{"key":"e_1_2_6_7_2","unstructured":"H4H\u2010EW\u2010LGAA dose escalation study.Study on file (Eli Lilly and Co)"},{"key":"e_1_2_6_8_2","unstructured":"H4H\u2010EW\u2010LWAB multiple dose safety study.Study on file (Eli Lilly and Co)"},{"key":"e_1_2_6_9_2","unstructured":"H4H\u2010EW\u2010LGAD study in patients with well controlled epilepsy.Study on file (Eli Lilly and Co)"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)80512-5"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199808000-00013"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200008000-00016"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01251.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.170"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1996.tb00518.x"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1528-1157.2003.128902.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1528-1157.2003.128902.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T20:51:45Z","timestamp":1697230305000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1528-1157.2003.128902.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["10.1046\/j.1528-1157.2003.128902.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1528-1157.2003.128902.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1]]}}}